Literature DB >> 18771816

Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.

Reisuke H Takahashi1, Estibaliz Capetillo-Zarate, Michael T Lin, Teresa A Milner, Gunnar K Gouras.   

Abstract

Although beta-amyloid (Abeta) plaques and tau neurofibrillary tangles are hallmarks of Alzheimer's disease (AD) neuropathology, loss of synapses is considered the best correlate of cognitive decline in AD, rather than plaques or tangles. How pathological Abeta and tau aggregation relate to each other and to alterations in synapses remains unclear. Since aberrant tau phosphorylation occurs in amyloid precursor protein (APP) Swedish mutant transgenic mice, and since neurofibrillary tangles develop in triple transgenic mice harboring mutations in APP, tau and presenilin 1, we utilized these well-characterized mouse models to explore the relation between Abeta and tau pathologies. We now report that pathological accumulation of Abeta and hyperphosphorylation of tau develop concomitantly within synaptic terminals. Copyright 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771816      PMCID: PMC2909664          DOI: 10.1016/j.neurobiolaging.2008.07.021

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  45 in total

1.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Nicole B Terio; Corrinne M Peterhoff; Robert Durham; Marc Mercken; Pankaj D Mehta; Joseph Buxbaum; Vahram Haroutunian; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

2.  A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease.

Authors:  G A Jicha; E Lane; I Vincent; L Otvos; R Hoffmann; P Davies
Journal:  J Neurochem       Date:  1997-11       Impact factor: 5.372

3.  Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice.

Authors:  Marlen Knobloch; Uwe Konietzko; Danielle C Krebs; Roger M Nitsch
Journal:  Neurobiol Aging       Date:  2006-07-31       Impact factor: 4.673

4.  Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium.

Authors:  Irina Alafuzoff; Maria Pikkarainen; Thomas Arzberger; Dietmar R Thal; Safa Al-Sarraj; Jeanne Bell; Istvan Bodi; Herbert Budka; Estibaliz Capetillo-Zarate; Isidro Ferrer; Ellen Gelpi; Stephen Gentleman; Giorgio Giaccone; Nikolaos Kavantzas; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Camelia Monoranu; Piero Parchi; Efstratios Patsouris; Wolfgang Roggendorf; Christine Stadelmann; Nathalie Streichenberger; Fabricio Tagliavini; Hans Kretzschmar
Journal:  Acta Neuropathol       Date:  2008-03-15       Impact factor: 17.088

5.  Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice.

Authors:  Celina V Zerbinatti; Suzanne E Wahrle; Hyungjin Kim; Judy A Cam; Kelly Bales; Steven M Paul; David M Holtzman; Guojun Bu
Journal:  J Biol Chem       Date:  2006-09-29       Impact factor: 5.157

6.  beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity.

Authors:  H Zheng; M Jiang; M E Trumbauer; D J Sirinathsinghji; R Hopkins; D W Smith; R P Heavens; G R Dawson; S Boyce; M W Conner; K A Stevens; H H Slunt; S S Sisoda; H Y Chen; L H Van der Ploeg
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Authors:  Salvatore Oddo; Lauren Billings; J Patrick Kesslak; David H Cribbs; Frank M LaFerla
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

9.  Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356.

Authors:  J M Litersky; G V Johnson; R Jakes; M Goedert; M Lee; P Seubert
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

Review 10.  Alzheimer disease models and human neuropathology: similarities and differences.

Authors:  Charles Duyckaerts; Marie-Claude Potier; Benoît Delatour
Journal:  Acta Neuropathol       Date:  2007-11-16       Impact factor: 17.088

View more
  65 in total

1.  Beta-amyloid induced changes in A-type K⁺ current can alter hippocampo-septal network dynamics.

Authors:  Xin Zou; Damien Coyle; KongFatt Wong-Lin; Liam Maguire
Journal:  J Comput Neurosci       Date:  2011-09-21       Impact factor: 1.621

2.  Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.

Authors:  Davide Tampellini; Estibaliz Capetillo-Zarate; Magali Dumont; Zhenyong Huang; Fangmin Yu; Michael T Lin; Gunnar K Gouras
Journal:  J Neurosci       Date:  2010-10-27       Impact factor: 6.167

3.  Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Authors:  Gunnar K Gouras; Katarina Willén; Davide Tampellini
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

4.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

Review 5.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 6.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

7.  Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Mubeen A Ansari; Kelly N Roberts; Frederick A Schmitt; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Authors:  Magdalena A Kuszczyk; Sandrine Sanchez; Joanna Pankiewicz; Jungsu Kim; Malgorzata Duszczyk; Maitea Guridi; Ayodeji A Asuni; Patrick M Sullivan; David M Holtzman; Martin J Sadowski
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

9.  Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.

Authors:  Davide Tampellini; Gunnar K Gouras
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.